JP2013512889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512889A5 JP2013512889A5 JP2012541584A JP2012541584A JP2013512889A5 JP 2013512889 A5 JP2013512889 A5 JP 2013512889A5 JP 2012541584 A JP2012541584 A JP 2012541584A JP 2012541584 A JP2012541584 A JP 2012541584A JP 2013512889 A5 JP2013512889 A5 JP 2013512889A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sheep
- difficile
- toxin
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0921288.7A GB0921288D0 (en) | 2009-12-04 | 2009-12-04 | Therapies for preventing or suppressing clostridium difficile infection |
| GB0921288.7 | 2009-12-04 | ||
| PCT/GB2010/050288 WO2010094970A1 (en) | 2009-02-20 | 2010-02-19 | Antibodies to clostridium difficile toxins |
| GBPCT/GB2010/050288 | 2010-02-19 | ||
| PCT/GB2010/052035 WO2011067616A1 (en) | 2009-12-04 | 2010-12-06 | Therapies for preventing or suppressing clostridium difficile infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512889A JP2013512889A (ja) | 2013-04-18 |
| JP2013512889A5 true JP2013512889A5 (https=) | 2014-01-30 |
| JP5877161B2 JP5877161B2 (ja) | 2016-03-02 |
Family
ID=41641956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541584A Active JP5877161B2 (ja) | 2009-12-04 | 2010-12-06 | クロストリジウム・ディフィシル感染を予防または抑制するための治療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8921529B2 (https=) |
| EP (1) | EP2506877B1 (https=) |
| JP (1) | JP5877161B2 (https=) |
| CN (1) | CN102740889A (https=) |
| BR (1) | BR112012013496A2 (https=) |
| CA (1) | CA2782639C (https=) |
| GB (1) | GB0921288D0 (https=) |
| MY (1) | MY158712A (https=) |
| SG (1) | SG181127A1 (https=) |
| WO (1) | WO2011067616A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709428B2 (en) | 2009-02-20 | 2014-04-29 | Health Protection Agency | Antibodies to Clostridium difficile toxins |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| SMT201700124T1 (it) | 2010-09-03 | 2017-05-08 | Valneva Austria Gmbh | Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi |
| GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| AR086199A1 (es) * | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| US9505847B2 (en) * | 2011-08-22 | 2016-11-29 | Cnj Holdings Inc | Clostridium difficile antibodies |
| AU2012349753A1 (en) | 2011-12-08 | 2014-06-19 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| DE102011121237A1 (de) * | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| CN105142612A (zh) | 2013-03-08 | 2015-12-09 | 奇普拉股份有限公司 | 用于直肠给药的药物组合物 |
| EP2970400A1 (en) * | 2013-03-15 | 2016-01-20 | Sanofi Pasteur, Inc. | Toxoid, compositions and related methods |
| CA2910200A1 (en) * | 2013-04-22 | 2014-10-30 | Board Of Regents Of The University Of Oklahoma | Clostridium difficile vaccine and methods of use |
| JP6691477B2 (ja) | 2013-06-14 | 2020-04-28 | サノフィ パストゥール インコーポレイテッド | クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法 |
| US10513552B2 (en) | 2014-06-20 | 2019-12-24 | Immunimed Inc. | Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease |
| EP2957570B1 (en) * | 2014-06-20 | 2019-04-17 | Immunimed Inc. | Polyclonal antibodies against clostridium difficile and uses thereof |
| ES2672045T3 (es) * | 2014-07-25 | 2018-06-12 | Biosynth S.R.L. | Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas |
| EP3121272A1 (en) * | 2015-07-24 | 2017-01-25 | Zymetech ehf. | Novel fish trypsin isoforms and their use |
| US20190111001A1 (en) * | 2016-03-30 | 2019-04-18 | University Of Maryland, Baltimore | Microparticulate system for colonic drug delivery |
| GB201701404D0 (en) * | 2017-01-27 | 2017-03-15 | Micropharm Ltd | Therapies for treating inflammatory disorders |
| EP4168032A2 (en) | 2020-06-19 | 2023-04-26 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| GB202019817D0 (en) * | 2020-12-15 | 2021-01-27 | Univ Oxford Innovation Ltd | Ligand-binding polypeptides and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS608225A (ja) | 1983-06-29 | 1985-01-17 | Kowa Co | 腸管吸収医薬組成物 |
| US5601823A (en) * | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| WO1996007430A1 (en) | 1994-09-06 | 1996-03-14 | Galagen, Inc. | Therapeutic treatment of clostridium difficile associated diseases |
| CA2203504A1 (en) * | 1994-10-24 | 1996-05-02 | James A. Williams | Vaccine and antitoxin for treatment and prevention of c. difficile disease |
| US6096310A (en) | 1997-04-15 | 2000-08-01 | Bier; Milan | Oral immunotherapy of bacterial overgrowth |
| AU746859B2 (en) | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
| US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| EP2305293A3 (en) | 1997-10-20 | 2013-11-06 | Sanofi Pasteur Biologics Co. | Immunization against Clostridium difficile disease |
| US6074689A (en) | 1998-03-10 | 2000-06-13 | Immucell Corporation | Colonic delivery of protein or peptide compositions |
| US20020009429A1 (en) | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| GB0205206D0 (en) | 2002-03-06 | 2002-04-17 | Oxoid Ltd | Synthetic peptides |
| AU2003299527A1 (en) | 2002-06-17 | 2004-06-07 | Jimmy D. Ballard | Mutant of clostridium difficile toxin b and methods of use |
| WO2004003145A2 (en) * | 2002-06-28 | 2004-01-08 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| LT2857418T (lt) | 2004-02-06 | 2017-09-25 | University Of Massachusetts | Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas |
| CA2565368A1 (en) * | 2004-04-29 | 2005-11-24 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases |
| US20090087478A1 (en) | 2004-12-27 | 2009-04-02 | Progenics Pharmaceuticals (Nevada), Inc. | Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them |
| US7794721B2 (en) | 2006-12-13 | 2010-09-14 | Simon Michael R | Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith |
| CN101363867B (zh) | 2008-05-26 | 2012-12-19 | 北京庄笛浩禾生物医学科技有限公司 | 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法 |
| US8709428B2 (en) | 2009-02-20 | 2014-04-29 | Health Protection Agency | Antibodies to Clostridium difficile toxins |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
-
2009
- 2009-12-04 GB GBGB0921288.7A patent/GB0921288D0/en not_active Ceased
-
2010
- 2010-12-06 CA CA2782639A patent/CA2782639C/en active Active
- 2010-12-06 BR BR112012013496A patent/BR112012013496A2/pt not_active IP Right Cessation
- 2010-12-06 US US13/513,555 patent/US8921529B2/en active Active
- 2010-12-06 EP EP10787170.9A patent/EP2506877B1/en active Active
- 2010-12-06 CN CN2010800537789A patent/CN102740889A/zh active Pending
- 2010-12-06 MY MYPI2012002466A patent/MY158712A/en unknown
- 2010-12-06 WO PCT/GB2010/052035 patent/WO2011067616A1/en not_active Ceased
- 2010-12-06 JP JP2012541584A patent/JP5877161B2/ja active Active
- 2010-12-06 SG SG2012039616A patent/SG181127A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512889A5 (https=) | ||
| O'Brien-Simpson et al. | RgpA-Kgp peptide-based immunogens provide protection against Porphyromonas gingivalis challenge in a murine lesion model | |
| JP2012504660A5 (https=) | ||
| ES2618605T3 (es) | Oligopéptidos de metaloproteinasas y su uso terapéutico | |
| JP2009520758A5 (https=) | ||
| CA2790219C (en) | Treatment or prevention of infection | |
| JP5661744B2 (ja) | 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用 | |
| Liu et al. | Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A | |
| AU2014257172B2 (en) | Clostridium difficile vaccine and methods of use | |
| EP3383884A1 (en) | Method for preventing or treating nosocomial pneumonia | |
| JP2017160238A (ja) | ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物 | |
| CN1437482A (zh) | 用于治疗变态反应的重组的或纯化的多克隆抗体 | |
| WO2007145760A3 (en) | Anthrax compositions and methods of use and production | |
| JP2015513314A5 (https=) | ||
| ES2551699T3 (es) | Composiciones, procedimientos y kits | |
| CN116406274A (zh) | 用于治疗冠状病毒的cd3抗体 | |
| US20230233667A1 (en) | Coronavirus vaccine | |
| Tsurumi et al. | Production of antibody against a synthetic peptide of Porphyromonas gingivalis 40-kDa outer membrane protein | |
| JP2006500386A (ja) | ペスト菌ｆ１抗原に特異的な抗体とペスト菌ｖ抗原に特異的な抗体のうちの１又は２種の抗体を含む抗エルシニアワクチン | |
| JP7439371B2 (ja) | Ｃａｎｄｉｄａ ａｕｒｉｓ感染症の治療方法 | |
| Kim et al. | Development of an equine antitoxin by immunizing the Halla Horse with the receptor-binding domain of botulinum neurotoxin type A1 | |
| TWI430808B (zh) | 外膜蛋白ａ於治療／預防／診斷中樞神經系統與周邊血液細菌感染之用途 | |
| WO2024229199A2 (en) | Humoral modulation in vaccinated and virally infected subjects with granulocyte-macrophage colony-stimulating factor (gm-csf) | |
| WO2022253193A1 (zh) | 一种新型冠状病毒疫苗多肽及其纳米乳制剂在预防新冠野毒株和突变株感染中的应用 | |
| WO2024229195A1 (en) | Viral infection modulation in vaccinated subjects treated with granulocyte-macrophage colony-stimulating factor (gm-csf) |